Telix Pharmaceuticals | TLX

Stock Price
13.60
Daily Change
-0.20 -1.45%
Monthly
-19.48%
Yearly
-22.51%
Q3 Forecast
13.73

Peers Price Chg Day Year Date
Cochlear 299.88 1.35 0.45% 2.92% Sep/08
CSL 213.37 4.12 1.97% -28.97% Sep/08
Integral Diagnostics 2.91 0.01 0.34% 11.92% Sep/08
Mesoblast 2.21 0.09 4.25% 138.92% Sep/08
Medical Developments International 0.57 -0.01 -0.87% 35.71% Sep/08
Mayne Pharma 4.50 -0.78 -14.77% -6.44% Sep/08
Neuren Pharmaceuticals 20.80 0.32 1.56% 51.27% Sep/08
Paradigm Biopharmaceuticals 0.28 -0.01 -1.79% 17.02% Sep/08
Pacific Edge 0.14 0.001 0.71% 35.24% Sep/08
Polynovo 1.47 -0.06 -3.61% -37.45% Sep/08
PYC Therapeutics 1.26 0.01 0.80% 5.00% Sep/08
Ramsay Health Care 33.89 0.23 0.68% -13.63% Sep/08
ResMed 41.92 -0.34 -0.80% 14.44% Sep/08
Sonic Healthcare 22.96 0.02 0.09% -14.90% Sep/08

Indexes Price Day Year Date
ASX200 8800 -21.63 -0.24% 10.16% Sep/08

Telix Pharmaceuticals Ltd traded at 13.60 this Monday September 8th, decreasing 0.20 or 1.45 percent since the previous trading session. Looking back, over the last four weeks, Telix Pharmaceuticals lost 19.48 percent. Over the last 12 months, its price fell by 22.51 percent. Looking ahead, we forecast Telix Pharmaceuticals Ltd to be priced at 13.73 by the end of this quarter and at 13.50 in one year, according to Trading Economics global macro models projections and analysts expectations.

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.